AngioDynamics (AngioDynamics) Shares Outstanding (Diluted Average)

: 40.2 Mil (As of Feb. 2024)

View and export this data going back to 2004. Start your Free Trial

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. AngioDynamics's average diluted shares outstanding for the quarter that ended in Feb. 2024 was 40.2 Mil.

AngioDynamics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for AngioDynamics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Shares Outstanding (Diluted Average)

37.49

37.96

38.34

39.01

39.48

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Shares Outstanding (Diluted Average)																39.51	39.61	39.97	40.22	40.23

AngioDynamics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

AngioDynamics (NAS:ANGO) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

AngioDynamics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (AngioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

Executives

Lorinda Burgess	director	22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff	director	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea	officer: SVP/GM, VIT	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel	officer: SVP Global Operations and R&D	400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini	officer: SVP International	C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge	officer: SVP and General Counsel	14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer	director, officer: President and CEO	COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson	director
Chad Thomas Campbell	officer: SVP/GM, Vascular Access	140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan	officer: SVP Quality and Regulatory	ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig	officer: SVP and General Counsel	C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould	director	247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher	officer: SVP and GM of Oncology	14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner	officer: EVP and CFO	C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421